# US 2020/0390765 A1 · Methods for modulating splicing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390765 A1
- Document ID: US20200390765A1
- Status: Published application
- Kind: A1
- Application number: 16/813,069
- Filed: 2020-03-09
- Published: 2020-12-17
- Earliest claimed: 2019-06-17
- Assignees: Skyhawk Therapeutics, Inc.
- Applicants: Skyhawk Therapeutics, Inc.
- Inventors: Michael Luzzio; Kathleen McCarthy; Botao Liu
- Web page: https://patentgrep.com/patent/US20200390765A1

## CPC

- A61K 31/501: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods of use of small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.

## Claims

### Claim 1

A method of decreasing expression of a target protein, comprising contacting a small molecule splicing modulator (SMSM) to a pre-mRNA encoded by a gene of the target protein or a cell comprising the pre-mRNA,
wherein the SMSM binds to the pre-mRNA to generate a spliced product of the pre-mRNA;
wherein the spliced product of the pre-mRNA comprises
i) a poison exon,
ii) a frame-shift and a premature termination codon downstream of the frame-shift, or
iii) a poison exon and an intron immediately downstream of the poison exon;
wherein the spliced product of the pre-mRNA undergoes nonsense-mediated mRNA decay (NMD) and/or nuclear retention; and
wherein expression of the target protein encoded by the spliced product is decreased.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pre-mRNA comprises a splice site sequence with a bulged nucleotide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the expression of the target protein encoded by the spliced product is decreased by at least 30%.

### Claim 4 (depends on 1)

The method of claim 1, wherein
(a) the number of base pairs between the premature termination codon and the 3′ end of the poison exon is at least 50, or
(b) the number of base pairs between the premature termination codon and the 3′ end of the spliced product of the pre-mRNA is at least 50.

### Claim 5 (depends on 1)

The method of claim 1, wherein the SMSM binds to the pre-mRNA, a protein bound to the pre-mRNA, and/or an RNA bound to the pre-mRNA.

### Claim 6 (depends on 1)

The method of claim 1, wherein the SMSM modulates binding affinity of a splicing complex component to the pre-mRNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pre-mRNA comprises a splice site sequence and the SMSM modulates binding affinity of the splicing complex component to the pre-mRNA at the splice site sequence, upstream of the splice site sequence, or downstream of the splice site sequence.

### Claim 8 (depends on 7)

The method of claim 7, wherein the splice site sequence is a 5′ splice site sequence, a 3′ splice site sequence, a branch point splice site sequence, an exonic splicing enhancer (ESE) sequence, an exonic splicing silencer (ESS) sequence, an intronic splicing enhancer (ISE) sequence, an intronic splicing silencer (ISS) sequence, a polypyrimidine tract sequence, a cryptic splice site sequence, or any combination thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the gene does not comprise a mutation.

### Claim 10 (depends on 9)

The method of claim 9, wherein the mutation is associated with splicing of the pre-mRNA.

### Claim 11 (depends on 9)

The method of claim 9, wherein the mutation is associated with expansion of a portion of the pre-mRNA.

### Claim 12 (depends on 9)

The method of claim 9, wherein the mutation is associated with the expression level of the pre-mRNA or a protein encoded by the gene.

### Claim 13 (depends on 12)

The method of claim 12, wherein the mutation is associated with over-expression of the pre-mRNA or a protein encoded by the gene.

### Claim 14 (depends on 9)

The method of claim 9, wherein the mutation is associated with gain-of-function of a protein encoded by the gene.

### Claim 15 (depends on 9)

The method of claim 9, wherein the mutation is associated with a disease or a condition associated with expression level, over-expression, or gain-of-function of a protein encoded by the gene.

### Claim 16 (depends on 1)

The method of claim 1, wherein the SMSM is present at a concentration of at least about 1 nM.

### Claim 17 (depends on 1)

The method of claim 1, wherein the SMSM has a molecular weight of at most about 2000 Daltons.

### Claim 18 (depends on 1)

The method of claim 1, wherein the SMSM has a molecular weight of at least 100 Daltons.

### Claim 19 (depends on 1)

The method of claim 1, wherein the SMSM does not comprise a phosphodiester linkage.

### Claim 20

(canceled)
